Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Mobile SMART Exercise Support Program to Improve Fatigue in Lung Cancer Patients - A RCT

29 de mayo de 2022 actualizado por: Dr. Agnes Yuen-Kwan Lai, The University of Hong Kong

A Brief Mobile SMART Exercise Support Program to Improve Fatigue in Patients With Advanced Lung Cancer - A Pragmatic Randomized Controlled Trial With Outcome and Process Evaluation

Lung cancer (LC) is a common cancer in the world. Among all symptoms, Fatigue is considered as the most distressing medical condition of LC. Prior studies revealed that physical activity effectively relieve fatigue and related problems. The current study attempt to explore the effectiveness of SMART Exercise Support Program (SES) with the use of mobile instant messaging application, on reducing symptoms such as fatigue, and improving physical activity level, physical fitness performance, sleep quality and habits, and quality of life in advanced lung cancer (ALC) patients.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Descripción detallada

Lung cancer (LC) is the most and second most common cancer globally and locally, respectively. Nearly half of LC patients are diagnosed in the advanced stage. Fatigue is perceived to be the most distressing symptom. Physical activity has been proposed as an alternative treatment to relieve fatigue and related problems.

Mobile instant messaging applications (e.g. WhatsApp/WeChat) are popular and inexpensive for interactive messaging. A systematic review showed a majority of messaging interventions were effective in diabetes self-management, weight loss, physical activity (PA), smoking cessation, and medication adherence.

The proposed randomized controlled trial (RCT) aims to examine the effectiveness of SES on relieving fatigue, pain, dyspnea, happiness, anxiety and depression symptoms, physical activity level, physical fitness performance, sleep quality and habits, and quality of life in ALC patients (SES group), compared to the General Hygiene Information (GHI, control) group.

Questionnaires and simple fitness tests will be used at baseline, 6-week, and 24-week assessments. Qualitative feedback will be obtained at the completion of the trial.

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

120

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Agnes Lai, PhD
  • Número de teléfono: 852-3917-6328
  • Correo electrónico: agneslai@hku.hk

Copia de seguridad de contactos de estudio

  • Nombre: George Cheung, MPhil
  • Número de teléfono: 852-3917-6563
  • Correo electrónico: ocgeorge@hku.hk

Ubicaciones de estudio

      • Hong Kong, Hong Kong
        • Reclutamiento
        • Queen Mary Hospital
        • Contacto:
          • Agnes Lai, PhD
          • Número de teléfono: 852-3917-6283
          • Correo electrónico: agneslai@hku.hk
        • Contacto:
          • David Lam, PhD
          • Número de teléfono: 852-2255-4455
          • Correo electrónico: slnga@hku.hk
        • Investigador principal:
          • Agnes YK Lai, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 100 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Aged 18 years and above;
  • Diagnosis of Stage III or IV non-small cell lung cancer;
  • Edmonton Symptom Assessment System Scale fatigue symptom score ≥4 out of 10
  • Self-reported engagement of <150 minutes of moderate intensity PA each week,
  • Ambulatory and capable of all self-care activities (European Co-operative Oncology Group (ECOG) Performance Status of ≤2)
  • Either undergoing or finished oncology therapy, biological agents and/or support care;
  • Mentally, cognitively and physically fit to join the trial as determined by the doctor in-charge and responsible clinical investigators;
  • Able to speak and read Chinese;
  • Willing to complete the patient-reported outcome questionnaire;
  • Completion of the Physical Activity Readiness Questionnaire; and
  • Possession of a smartphone with instant messaging functions such as WhatsApp or WeChat.

Exclusion Criteria:

  • Those preparing for lung operation;
  • Skeletal fragility;
  • Serious active infection;
  • Inability to walk;
  • Previously untreated symptomatic brain metastases;
  • Severe respiratory insufficiency;
  • Uncontrolled pain; or
  • Diagnosed psychiatric illness with or without medication such as major depressive disorder.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Brief mobile SMART Exercise Support Program
Patients will receive a brief SMART Exercise individual session with instant messages and telephone coaching for exercise habit formation and maintenance.
Patients will receive 1) a brief SMART Exercise individual face-to-face session; 2) a theory-based instant messaging (WhatsApp/WeChat) and telephone-delivered health coaching on a 2-stage tapering schedule. Stage 1 (week 1 to 6): daily messages and two biweekly phone calls for exercise habit formation. Stage 2 (week 7 to 12): messages twice a week and monthly phone calls for exercise habit maintenance.
Comparador de placebos: General Hygiene Information (GHI)
Patients will receive an individual session, instant messages and telephone coaching regarding general hygiene information.
Patients will receive 1) a brief SMART Exercise individual face-to-face session; 2) a theory-based instant messaging (WhatsApp/WeChat) and telephone-delivered health coaching on a 2-stage tapering schedule. Stage 1 (week 1 to 6): daily messages and two biweekly phone calls for exercise habit formation. Stage 2 (week 7 to 12): messages twice a week and monthly phone calls for exercise habit maintenance.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in fatigue level
Periodo de tiempo: Baseline and 6 weeks
Measured by a 13-item Functional Assessment of Cancer Therapy - Fatigue subscale. The level of fatigue is measured on a five-point Likert scale. The scale range is 0 to 52, with 0 being the worst possible score and 52 being the best possible score indicating no fatigue.
Baseline and 6 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in fatigue level
Periodo de tiempo: Baseline and 6 months
Measured by a 13-item Functional Assessment of Cancer Therapy - Fatigue subscale. The level of fatigue is measured on a five-point Likert scale. The scale range is 0 to 52, with 0 being the worst possible score and 52 being the best possible score indicating no fatigue.
Baseline and 6 months
Change in anxiety symptoms
Periodo de tiempo: Baseline, 6 weeks, 6 months
Measured by a 7-item Generalised Anxiety Disorder Assessment. Each item asks the individual to rate the severity of his or her symptoms with a 4-point Likert scale. The total score ranges from 0 to 21. The higher scores the greater severity of anxiety symptoms.
Baseline, 6 weeks, 6 months
Change in depression symptoms
Periodo de tiempo: Baseline, 6 weeks, 6 months
Measured by a 9-item Patient Health Questionaire. Each item asks the individual to rate the severity of his or her symptoms with a 4-point Likert scale. The total score ranges from 0 to 27. The higher scores the greater severity of depression symptoms.
Baseline, 6 weeks, 6 months
Change in physical activity level
Periodo de tiempo: Baseline, 6 weeks, 6 months
Measured the days and duration of physical activity level and sitting time in the past 7 days by the International Physical Activity Questionnaire (short version) with 4 questions.
Baseline, 6 weeks, 6 months
Change in sleep quality
Periodo de tiempo: Baseline, 6 weeks, 6 months
Measured by 7-item Severe Insomnia Index. Each item asks the individual to rate the severity of his or her symptoms with a 4-point Likert scale. The total score ranges from 0 to 28. The higher scores the greater severity of insomnia.
Baseline, 6 weeks, 6 months
Change in health-related quality of life
Periodo de tiempo: Baseline, 6 weeks, 6 months
Measured by a 30-item European Organization for Research and Treatment of Cancer and Lung Module. It contains five functioning scales (physical, social, role, cognitive, and emotional functioning), and eight symptom scales (fatigue, nausea/vomiting, pain, dyspnea, sleep disturbances, appetite loss, constipation, and diarrhoea), and financial impact, and overall quality of life. All scale scores are linearly converted to a range from 0 to 100. Higher scores indicate better functioning for the functioning scales and global QOL; for the symptom scales, higher scores indicate higher symptom burden.
Baseline, 6 weeks, 6 months
Change in happiness level
Periodo de tiempo: Baseline, 6 weeks, 6 months
Measured by 4-item Subjective Happiness Scale with a 7-point Likert scale. Total scores range from 4 to 28. The highest scores reflect greater happiness.
Baseline, 6 weeks, 6 months
Change in cancer-related symptoms
Periodo de tiempo: Baseline, 6 weeks and 6 months
Measured by 3 items of the Edmonton Symptom Assessment System Scale. The severity at the time of assessment of each symptom is rated from 0 to 10 on a numerical scale, 0 meaning that the symptom is absent and 10 that it is of the worst possible severity.
Baseline, 6 weeks and 6 months
Change in acceptance of illness
Periodo de tiempo: Baseline, 6 weeks and 6 months
Measured by a 5-item subscale of Peace, Equanimity, and Acceptance in the Cancer Experience questionnaire
Baseline, 6 weeks and 6 months
Change in exercise self-efficacy
Periodo de tiempo: Baseline, 6 weeks and 6 months
Measured by a question with a scale from 0 to 10; "0" indicates no exercise self-efficacy, while "10" indicates highest level of exercise self-efficacy.
Baseline, 6 weeks and 6 months
Change in social and family support
Periodo de tiempo: Baseline, 6 weeks and 6 months
Measured by 8-item family and friend subscales of multidimensional Scale of Perceived Social Support with a 7-point Likert scale. Each scale ranges from 4 to 28. A higher score equates with higher social support.
Baseline, 6 weeks and 6 months
Change in grip strength
Periodo de tiempo: Baseline, 6 weeks and 6 months
Measured by a dynamometer
Baseline, 6 weeks and 6 months
Change in lower limb strength
Periodo de tiempo: Baseline, 6 weeks, and 6 months
Measured by 30-second chair stand test.
Baseline, 6 weeks, and 6 months
Change in balance
Periodo de tiempo: Baseline, 6 weeks and 6 months
Measured by single-leg-stance test
Baseline, 6 weeks and 6 months
Change in flexibility
Periodo de tiempo: Baseline, 6 weeks, and 6 months
Measured by chair sit and reach test
Baseline, 6 weeks, and 6 months
Change in objective physical activity levels, including duration, frequency and intensity
Periodo de tiempo: Baseline, 6 weeks, and 6 months
Measured by a waist-worn accelerometer
Baseline, 6 weeks, and 6 months
Change in sleep and wake intervals
Periodo de tiempo: Baseline, 6 weeks , and 6 months
Measured by watch-like activity monitor
Baseline, 6 weeks , and 6 months
Change in exercise capacity
Periodo de tiempo: Baseline, 6 weeks and 6 months
Measured by a 6-min walk test
Baseline, 6 weeks and 6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Agnes YK Lai, PhD, School of Nursing, The University of Hong Kong

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de mayo de 2022

Finalización primaria (Anticipado)

30 de junio de 2023

Finalización del estudio (Anticipado)

30 de septiembre de 2024

Fechas de registro del estudio

Enviado por primera vez

11 de abril de 2022

Primero enviado que cumplió con los criterios de control de calidad

11 de abril de 2022

Publicado por primera vez (Actual)

15 de abril de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de junio de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

29 de mayo de 2022

Última verificación

1 de mayo de 2022

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

No

Descripción del plan IPD

For those who want the patient data, please contact PI directly by written email.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir